

Opto Circuits Q3FY11 consolidated Net Sales at Rs. 418 crores and PAT at Rs. 96 crores

EPS for the quarter is at Rs. 5.22 (Basic) and Rs. 5.13 (Diluted)

**Bengaluru, India
January 18, 2010**

Opto Circuits (India) Ltd. (OCI), India's leading developer and manufacturer of medical equipment and interventional devices, today announced its financial results for the third quarter and nine months ending December 31st 2010.

For the third quarter ending December 31, 2010 (Q3FY11)

- Consolidated Net Sales stood at Rs. 417.65 crores and Standalone Net Sales stood at Rs. 158.89 crores.
- Consolidated EBITDA at Rs. 133.27 crores and Standalone EBITDA at Rs 65.40 crores.
- Consolidated PAT at Rs. 95.67 crores and Standalone PAT at Rs. 56.22 crores.

For the nine months ending December 31, 2010 (FY11)

- Consolidated Net Sales stood at Rs. 1041.10 crores and Standalone Net Sales stood at Rs. 429.59 crores.
- Consolidated EBITDA at Rs. 337.27 crores and Standalone EBITDA at Rs. 186.46 crores.
- Consolidated PAT at Rs. 256.15 crores and Standalone PAT at Rs. 164.30 crores.

MANAGEMENT COMMENT

Vinod Ramnani, Chairman and Managing Director, OCI: "We've had an exciting third quarter in terms of business growth and expansion. We've performed well across important segments and key geographies."

"Acquiring the gold standard product line at Cardiac Science Corporation has been the latest highlight of our endeavor to achieve scale and brand equity in the highly competitive medtech industry. The integration process has begun and our teams are on the job to ensure a seamless amalgamation of our non-invasive business synergies. We remain committed to our shareholders and in our objective to create maximum value for them."

KEY HIGHLIGHTS OF THE QUARTER

Opto acquired 100 percent of the capital stock of US-based Cardiac Science, a company that develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems.

Cardiac Science added two ECGs under its Burdick brand, known for their accuracy, reliability, and ease of use. The ECGs, available only in the U.S., deliver built-in, bi-directional communication so customers can connect to leading EMRs.

Criticare Systems Inc. (CSI) released its next generation CO₂/N₂O module which is a compact version of the proven Criticare Systems Poet® series CO₂ detection technology, which, using non-dispersive infrared technology, will measure inspired and expired CO₂ and N₂O gases.

Eurocor GmbH received CE (Conformité Européen) mark on coronary bare metal stent brands eMagic (an uncoated stent on cobalt chromium) and eFlex (an uncoated stent on a stainless steel base).

The company also received registration from Drug Controller General of India for its PTCA drug-coated stent delivery system – MAGICAL® ; a combination of a drug coated balloon and a bare metal stent .

Eurocor hosted the global launch of FREEWAY™, the latest second-generation, percutaneous transluminal angioplasty (PTA) balloon technology designed for the treatment of critical limb ischemia associated with peripheral arterial disease in UK. The launch was attended by over 70 medical interventionalists. This was followed by the European launch meeting in Valencia, Italy.

NOTES TO EDITOR

a) Q3FY11 results include the most latest acquisition of Cardiac Science and 9MFY11 results include our 3 acquisitions during the year i.e. - N.S. Remedies, Unetixs Vascular and Cardiac Science

b) Opto Circuits' control of Cardiac Science was established in December 2010; only one month (December 2010) results of Cardiac Science are factored into the consolidated numbers. Therefore, Q3FY11 and 9MFY11 Profit and Loss numbers are not comparable to prior year numbers

c) Considering that the Cardiac Science reporting period for Q3FY11 Consolidated Results is less than a month from the acquisition date, certain values related to this acquisition have been considered at provisional values

DISCLAIMER

Statements made in this Investor Update describing the company's objectives, projections, estimates, expectations may be "Forward-looking Statements" within the meaning of applicable securities' laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand supply and price conditions in the domestic and overseas markets in which the company operates, changes in the government regulations, tax laws and other statutes and other incidental factors.